Table 1.
Pre-treatment Characteristics for Patients Included in Analysis
| Characteristics | STAD+RT (n=762) | LTAD+RT (n=758) | p | |||
|---|---|---|---|---|---|---|
| Age, years | 0.39 | |||||
| Mean | 69.4 | 69.7 | ||||
| Median (range) | 70 (43–87) | 70 (43–88) | ||||
| No. | % | No. | % | |||
| Race | 0.41 | |||||
| White | 642 | 84.3 | 637 | 84.0 | ||
| Hispanic | 17 | 2.2 | 10 | 1.3 | ||
| African American | 92 | 12.1 | 105 | 13.9 | ||
| Native Hawaiian, other Pacific Islanders, American Indian, or Alaska Native | 6 | 0.8 | 4 | 0.5 | ||
| Unknown | 5 | 0.7 | 2 | 0.3 | ||
| PSA, ng/mL | 0.88 | |||||
| <=30 | 510 | 66.9 | 510 | 67.3 | ||
| >30 | 252 | 33.1 | 248 | 32.7 | ||
| Karnofsky Status, % | 0.04 | |||||
| 70 | 11 | 1.4 | 2 | 0.3 | ||
| 80 | 54 | 7.1 | 48 | 6.3 | ||
| 90 | 376 | 49.3 | 358 | 47.2 | ||
| 100 | 321 | 42.1 | 350 | 46.2 | ||
| Intercurrent Disease | 0.89 | |||||
| No | 253 | 33.2 | 246 | 32.5 | ||
| Yes | 503 | 66.0 | 508 | 67.0 | ||
| Unknown | 6 | 0.8 | 4 | 0.5 | ||
| Clinical Stage | 0.07 | |||||
| T2 | 347 | 45.5 | 344 | 45.4 | ||
| T3 | 394 | 51.7 | 376 | 49.6 | ||
| T4 | 21 | 2.8 | 38 | 5.0 | ||
| Pathological Nodal Stage | 0.63 | |||||
| NX | 657 | 86.2 | 648 | 85.5 | ||
| N0 | 70 | 9.2 | 81 | 10.7 | ||
| N1 | 24 | 3.2 | 18 | 2.4 | ||
| N2 | 11 | 1.4 | 11 | 1.5 | ||
| Institutional Gleason Score | 0.34 | |||||
| 2 – 5 | 142 | 18.6 | 137 | 18.1 | ||
| 6 | 149 | 19.6 | 154 | 20.3 | ||
| 7 | 226 | 29.7 | 251 | 33.1 | ||
| 8 – 10 | 187 | 24.5 | 174 | 23.0 | ||
| Unknown | 58 | 7.6 | 42 | 5.5 | ||